Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > FDA guides on how AA can be converted to full approval.

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Mar 26, 2023 2:26pm

210 Views

Post# 35361346

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:FDA guides on how AA can be converted to full approval.

The pre-clinical biotech company Trillium Therapeutics had a market cap of $600 million on Friday August 20, 2021 and then on the morning of Monday August 23, 2021 TRIL opened for trading with a market cap of US$2.3 Billion with the announcement of Pfizer's acquistion over the weekend. Woof Woof.

In ONCY's case this company has multiple cancer indications which represent multiples of value to TRIL's US$2.3 Billion acquisition price.

<< Previous

Bullboard Posts

Next >>

Stockhouse DealRoom opens new Australian opportunities